KHAV Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 6

KHAV General Information

Description

Developer of drug therapeutics designed to find cures and resistance for various diseases. The company specializes in providing vaccinations for diseases like bronchitis, metapneumovirus infection, and Gambero disease, enabling healthcare professionals to provide patients with cures for these diseases.

Contact Information

Website
www.khav.co.kr
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 261-34, Sagab 1-gil, Seoun-myeon
  • Anseong, Gyeonggi
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 261-34, Sagab 1-gil, Seoun-myeon
  • Anseong, Gyeonggi
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

KHAV Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC 01-Jan-2021 Completed Generating Revenue
1. Seed Round 01-Jan-2020 Completed Generating Revenue
To view KHAV’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

KHAV Patents

KHAV Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025116613-A1 Pharmaceutical composition for cancer treatment, comprising recombinant newcastle disease virus vectors Inactive 29-Nov-2023
WO-2024128804-A1 Sars-cov-2 virus vaccine Inactive 14-Dec-2022
EP-4560014-A1 Attenuated strain of avian infectious bronchitis virus and vaccine composition containing same Pending 22-Jul-2022
EP-4560014-A4 Attenuated strain of avian infectious bronchitis virus and vaccine composition containing same Pending 22-Jul-2022
WO-2024019579-A1 Attenuated strain of avian infectious bronchitis virus and vaccine composition containing same Inactive 22-Jul-2022 A61P31/14
To view KHAV’s complete patent history, request access »

KHAV Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Brick (South Korea) Venture Capital Minority
InterVest Venture Capital Minority
KG Zeroin Corporation Minority
Loftyrock Investment Venture Capital Minority
Simpac Corporation Minority
You’re viewing 5 of 6 investors. Get the full list »

KHAV FAQs

  • When was KHAV founded?

    KHAV was founded in 2014.

  • Where is KHAV headquartered?

    KHAV is headquartered in Anseong, South Korea.

  • What industry is KHAV in?

    KHAV’s primary industry is Drug Discovery.

  • Is KHAV a private or public company?

    KHAV is a Private company.

  • What is KHAV’s current revenue?

    The current revenue for KHAV is .

  • Who are KHAV’s investors?

    Brick (South Korea), InterVest, KG Zeroin, Loftyrock Investment, and Simpac are 5 of 6 investors who have invested in KHAV.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process